These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

80 related items for PubMed ID: 3353159

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Serum concentrations of the type I and III procollagen propeptides as biochemical markers of growth velocity in healthy infants and children and in children with growth disorders.
    Trivedi P, Risteli J, Risteli L, Hindmarsh PC, Brook CG, Mowat AP.
    Pediatr Res; 1991 Sep; 30(3):276-80. PubMed ID: 1945568
    [Abstract] [Full Text] [Related]

  • 4. Serum procollagen type 1 amino-terminal propeptide (P1NP) as an early predictor of the growth response to growth hormone treatment: Comparison of intrauterine growth retardation and idiopathic short stature.
    Gascoin-Lachambre G, Trivin C, Brauner R, Souberbielle JC.
    Growth Horm IGF Res; 2007 Jun; 17(3):194-200. PubMed ID: 17321775
    [Abstract] [Full Text] [Related]

  • 5. Twenty-four-hour osteocalcin, carboxyterminal propeptide of type I procollagen, and aminoterminal propeptide of type III procollagen rhythms in normal and growth-retarded children.
    Saggese G, Baroncelli GI, Bertelloni S, Cinquanta L, DiNero G.
    Pediatr Res; 1994 Apr; 35(4 Pt 1):409-15. PubMed ID: 8047377
    [Abstract] [Full Text] [Related]

  • 6. Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: high predictive value of the carboxyterminal propeptide of type I procollagen.
    Marini JC, Hopkins E, Glorieux FH, Chrousos GP, Reynolds JC, Gundberg CM, Reing CM.
    J Bone Miner Res; 2003 Feb; 18(2):237-43. PubMed ID: 12568401
    [Abstract] [Full Text] [Related]

  • 7. Radioimmunoassay for type I procollagen in growth hormone-deficient children before and during treatment with growth hormone.
    Carey DE, Goldberg B, Ratzan SK, Rubin KR, Rowe DW.
    Pediatr Res; 1985 Jan; 19(1):8-11. PubMed ID: 3969319
    [Abstract] [Full Text] [Related]

  • 8. Growth velocity, growth hormone therapy, and serum concentrations of the amino-terminal propeptide of type III procollagen.
    Trivedi P, Hindmarsh P, Risteli J, Risteli L, Mowat AP, Brook CG.
    J Pediatr; 1989 Feb; 114(2):225-30. PubMed ID: 2915282
    [Abstract] [Full Text] [Related]

  • 9. Low dose recombinant human growth hormone normalizes bone metabolism and cortical bone density and improves trabecular bone density in growth hormone deficient adults without causing adverse effects.
    Amato G, Izzo G, La Montagna G, Bellastella A.
    Clin Endocrinol (Oxf); 1996 Jul; 45(1):27-32. PubMed ID: 8796135
    [Abstract] [Full Text] [Related]

  • 10. [Procollagen III propeptide. Values in the course of pediatric celiac disease].
    Hauptmann C, Johannsen B.
    Monatsschr Kinderheilkd; 1992 Dec; 140(12):857-63. PubMed ID: 1491706
    [Abstract] [Full Text] [Related]

  • 11. Bone alkaline phosphatase and collagen markers as early predictors of height velocity response to growth-promoting treatments in short normal children.
    Crofton PM, Stirling HF, Schönau E, Kelnar CJ.
    Clin Endocrinol (Oxf); 1996 Apr; 44(4):385-94. PubMed ID: 8706304
    [Abstract] [Full Text] [Related]

  • 12. Serum levels of carboxyterminal propeptide of type I procollagen and aminoterminal propeptide of type III procollagen in children with growth retardation.
    Cinaz P, Hasanoglu E, Gökçora N, Dogukan S, Demir A.
    Mater Med Pol; 1994 Apr; 26(2):55-8. PubMed ID: 7745984
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency.
    Saggese G, Baroncelli GI, Bertelloni S, Cinquanta L, Di Nero G.
    J Pediatr; 1993 Jan; 122(1):37-45. PubMed ID: 8419613
    [Abstract] [Full Text] [Related]

  • 15. Normal osteoclastic and osteoblastic responses to exogenous growth hormone in patients with postmenopausal spinal osteoporosis.
    Kassem M, Brixen K, Blum WF, Mosekilde L, Eriksen EF.
    J Bone Miner Res; 1994 Sep; 9(9):1365-70. PubMed ID: 7817819
    [Abstract] [Full Text] [Related]

  • 16. Human growth hormone treatment in prepubertal children with achondroplasia.
    Weber G, Prinster C, Meneghel M, Russo F, Mora S, Puzzovio M, Del Maschio M, Chiumello G.
    Am J Med Genet; 1996 Feb 02; 61(4):396-400. PubMed ID: 8834055
    [Abstract] [Full Text] [Related]

  • 17. Different responses of bone alkaline phosphatase isoforms during recombinant insulin-like growth factor-I (IGF-I) and during growth hormone therapy in adults with growth hormone deficiency.
    Magnusson P, Degerblad M, Sääf M, Larsson L, Thorén M.
    J Bone Miner Res; 1997 Feb 02; 12(2):210-20. PubMed ID: 9041052
    [Abstract] [Full Text] [Related]

  • 18. Stimulation of collagen synthesis and linear growth by growth hormone in glucocorticoid-treated children.
    Allen DB, Goldberg BD.
    Pediatrics; 1992 Mar 02; 89(3):416-21. PubMed ID: 1741214
    [Abstract] [Full Text] [Related]

  • 19. Seven years of safety and efficacy of the recombinant human growth hormone Omnitrope in the treatment of growth hormone deficient children: results of a phase III study.
    Romer T, Saenger P, Peter F, Walczak M, Le Bouc Y, Khan-Boluki J, Berghout A.
    Horm Res; 2009 Mar 02; 72(6):359-69. PubMed ID: 19844125
    [Abstract] [Full Text] [Related]

  • 20. Relationship of procollagen type III propeptide-related antigens in serum to somatic growth in healthy children and patients with growth disorders.
    Danne T, Grüters A, Schuppan D, Quantas N, Enders I, Weber B.
    J Pediatr; 1989 Feb 02; 114(2):257-60. PubMed ID: 2915284
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.